Rhodiola rosea: evidence evaluation for Australian general practice

Rhodiola rosea — sold in Australian pharmacies and health-food retailers as a standardised root extract — is the more stimulating member of the adaptogen pair, marketed alongside ashwagandha as a natural strategy for stress-related fatigue, burnout, mild depression, and cognitive performance. This article evaluates the clinical trial record, the safety profile, and the Australian regulatory context, so general practitioners can respond to patient inquiries with grounded, proportionate advice.

The short answer is: the evidence is modest but real for stress-related fatigue and burnout, directionally positive but underpowered for mild depression, and insufficient for most other claimed indications. The most important clinical consideration is not the evidence for benefit but the bipolar contraindication — mania induction cases are documented, and screening for bipolar history is mandatory before recommending this supplement to any patient.

A. Core clinical — the AU general-practice framework

What rhodiola is

Rhodiola rosea L. (Crassulaceae; common names rose-root, golden root, Arctic root) is a perennial succulent native to the cold, high-latitude and high-altitude regions of Siberia, Scandinavia, Iceland, and the Pyrenees. Soviet-era military and aerospace research from the 1960s–80s — initially classified, later partially published by Panossian, Brekhman, and colleagues — established the adaptogen frame: a substance proposed to normalise physiological stress response bidirectionally rather than acting as a pure stimulant or sedative.

The TGA compositional guideline permits only Rhodiola rosea L. root or rhizome in listed medicines — not other Rhodiola species. This matters clinically because global supply is widely adulterated with cheaper Rhodiola crenulata, which lacks rosavins and fails label-claim assays in chromatographic surveys.

The two pharmacologically central compound groups are:

• Rosavins (rosavin, rosin, rosarin — cinnamyl alcohol glycosides): characteristic to authentic R. rosea, naturally present at approximately 3% in Siberian chemotypes
• Salidroside (a phenylpropanoid / tyrosol glucoside): present in multiple Rhodiola species; the basis for adulteration

Industry-standard extracts target 3% rosavins + 1% salidroside — the composition used in the principal RCTs (SHR-5, WS 1375, Rosavin reference materials). Products without detectable rosavins are almost certainly not authentic R. rosea.

Pharmacology and clinical signature

Salidroside is rapidly absorbed orally (Tmax 0.5–2 h, half-life 1.5–3 h) and metabolised partly via CYP3A4 and via monoamine oxidase A and B, with measurable weak in-vitro inhibition of both isoforms — the mechanistic basis for the bipolar mania caution and MAOI/SSRI interaction warnings (Van Diermen et al. 2009; Spanakis et al. 2023).

Additional proposed mechanisms — mostly from animal and in-vitro work — include HPA-axis modulation (attenuated cortisol awakening response in burnout, demonstrated in the Olsson 2009 RCT), catecholamine and serotonin modulation, beta-endorphin elevation, and mild antioxidant and anti-inflammatory effects.

Rhodiola’s clinical signature is consistently stimulating and activating — onset within hours of dosing, attentional sharpening, a subjective “wired but calm” quality. This distinguishes it sharply from ashwagandha’s sedating, anxiolytic profile. A patient with predominantly fatigue and low drive is a better candidate than one with predominantly anxiety and hyperarousal.

Prescribing approach

Indication: reasonable trial in stress-related fatigue and burnout (evidence tier 🟡) and mild depression where patient preference, mild severity, and bipolarity-negative screen align (evidence tier 🟡). Do not initiate without bipolar screen.

Dose: 200–400 mg once daily in the morning, standardised extract (3% rosavins + 1% salidroside). Do not exceed 600 mg per day — higher doses have been associated with mania case reports (Bersani et al. 2022).

Response window: 4–12 weeks for meaningful clinical effect; review at 4 weeks and 12 weeks; discontinue if no benefit at 12 weeks.

Timing: single morning dose; evening dosing risks insomnia in susceptible individuals.

Contraindications: bipolar disorder (absolute); pregnancy and breastfeeding; schizophrenia and psychotic disorders; MAOIs (absolute); concurrent SSRIs/SNRIs without monitoring.

B. Evidence appraisal — the clinical trial record

Stress-related fatigue and burnout

The best-supported indication. The Olsson 2009 RCT (SHR-5) enrolled 60 participants with stress-related fatigue and randomised them to 576 mg/day of standardised rhodiola extract versus placebo for 28 days. Burnout score (Pines burnout inventory) improved significantly versus placebo (p = 0.047), and the cortisol awakening response — a physiological burnout biomarker — was attenuated in the rhodiola group. The Edwards 2012 open-label study (WS 1375) in 101 participants with life-stress symptoms at 400 mg/day for four weeks showed consistent improvements across all stress symptom domains.

The Hung 2011 systematic review examined 11 rhodiola RCTs and concluded that while results were generally positive, methodological flaws preclude firm conclusions — small samples, heterogeneous outcome measures, and risk of bias were prominent concerns. This is the evidence ceiling for the stress-fatigue indication: one positive RCT plus supportive open-label data, qualified by the systematic review’s findings.

Mild depression

Mao et al. (2015) conducted the most cited trial — a three-arm RCT comparing rhodiola (340–680 mg/day), sertraline (50–100 mg/day), and placebo in 57 participants with mild-to-moderate major depressive disorder over 12 weeks. Sertraline showed greater response (odds ratio versus placebo: 1.9) than rhodiola (odds ratio: 1.4), and the between-group difference was not statistically significant. Rhodiola produced half the gastrointestinal adverse events of sertraline. The critical limitation: the study was not powered for non-inferiority between rhodiola and sertraline — it cannot be used to claim equivalence to antidepressant therapy.

An earlier Darbinyan et al. (2007) RCT in 89 participants with mild-to-moderate depression showed significant reductions in Beck and Hamilton depression scores versus placebo over six weeks.

The RANZCP 2020 Mood Disorder CPG does not list rhodiola as a treatment option. These findings support a trial in mild depression as an adjunct for patients with preference for herbal-first approaches — not as a substitute for guideline-aligned care.

Cognition and mental performance under stress

Small trials suggest acute benefits in attention, working memory, and psychomotor speed during high-stress periods (exams, shift work, deadline periods). Effect sizes are modest, samples small, and outcomes heterogeneous. This is the most commercially marketed indication and the weakest supported: treat patient claims of cognitive enhancement with proportionate scepticism while acknowledging the plausibility of a modest short-duration effect.

Athletic performance

The Lu et al. 2024 systematic review of rhodiola supplementation in sports performance found heterogeneous results, mostly small and poorly controlled trials, and no established ergogenic effect. Do not make performance claims to patients.

Generalised anxiety

Open-label data only. No placebo-controlled RCT in formally diagnosed anxiety disorder. The stimulating profile makes rhodiola a suboptimal choice for anxiety-predominant presentations — ashwagandha and first-line psychological therapies (CBT via Better Access) are better supported.

C. Safety profile and drug interactions

Bipolar disorder — absolute contraindication

Screen for bipolar history before every rhodiola recommendation. The Bersani et al. 2022 case report documents a manic episode precipitated by rhodiola, particularly at above-recommended doses. The proposed mechanism — partial MAO-A/B inhibition with stimulating monoaminergic effects — is biologically plausible for mania induction. Screen for prior manic or hypomanic episodes, family history of bipolar disorder, prior antidepressant-induced mood switching, and cyclothymic temperament. Any positive finding is a hard contraindication.

Drug interactions

The Spanakis et al. 2023 drug-interaction review and Van Diermen et al. 2009 pharmacology paper identify the following:

• MAOIs — additive effect, absolute contraindication
• SSRIs and SNRIs — theoretical serotonin syndrome risk at high dose and high baseline serotonergic load; use caution and monitor for serotonergic symptoms (restlessness, diaphoresis, tremor, diarrhoea, tachycardia)
• Stimulant medications (dexamphetamine, methylphenidate) — additive arousal; monitor for palpitations, hypertension, insomnia
• CYP3A4 substrates at narrow therapeutic index — warfarin, some statins, calcium-channel blockers, calcineurin inhibitors — potential interaction at high doses; practical risk at standard doses (200–400 mg) is low but worth documenting
• Mood stabilisers (lithium, valproate, lamotrigine) — theoretical mood-destabilisation risk in bipolar patients, reinforcing the contraindication

Hepatic safety

Rhodiola’s hepatic safety profile is currently cleaner than ashwagandha’s: no case series establishing hepatotoxicity with authentic R. rosea products, and PLoS ONE 2024 quality survey found no concerning signals in correctly identified R. rosea supplements. LiverTox does not list R. rosea as a cause of drug-induced liver injury, in contrast to ashwagandha where emerging case-series prompted a LiverTox entry. The adulteration risk — R. crenulata or unstandardised products — introduces uncertainty; buying AUST L-listed, species-verified product reduces this.

Pregnancy and breastfeeding

No human safety data. The EMA HMPC herbal monograph advises against use in pregnancy and breastfeeding. Recommend discontinuation when planning conception.

Insomnia

The stimulating profile means afternoon or evening dosing reliably disrupts sleep onset in a subset of users. Morning single dosing is non-negotiable.

D. Australian operations

TGA regulation

Rhodiola rosea root extract is listed on the TGA’s permitted ingredients list for the AUST L listed-medicines pathway — not AUST R registered medicines requiring full clinical dossier evaluation (TGA listed medicines). The TGA compositional guideline mandates Rhodiola rosea L. root or rhizome via aqueous or hydroethanolic (≤70% EtOH v/v) extraction; substitution with other Rhodiola species is a compliance breach.

AU brands and pricing (reviewed 2026-05-20)

• Blackmores Rhodiola + Stress — 200 mg, 3% rosavins + 1% salidroside; ARTG 367711; AUD ~$35/60 tablets
• Caruso’s Rhodiola 12000 — 300 mg dry-equivalent standardised extract; AUD ~$40
• BioCeuticals NeuroLift / Rhodiola — practitioner-only range; higher rosavin standardisation; AUD ~$50
• Mediherb Rhodiola and Ginseng — ARTG 509253; practitioner-only; AUD ~$55
• Typical out-of-pocket: AUD 30–60 per month for a therapeutic-dose AUST L-listed product

No PBS subsidy exists for any Rhodiola rosea product. All costs are out-of-pocket.

MBS context

There is no specific MBS item for rhodiola prescribing. Where burnout or stress-related fatigue co-exists with an adjustment disorder or mood comorbidity, Mental Health Care Plan preparation (MBS 2700/2715/2717) opens psychology referral under Better Access. This is frequently more important for the patient than the supplement: rhodiola is a reasonable adjunct to psychological care, not a substitute for it.

WADA status

Rhodiola rosea is not on the WADA 2026 Prohibited List and is usable by tested athletes. Remind patients in competitive sport about supplement contamination risk and to purchase AUST L-listed, batch-tested products.

E. Special populations

Adults with stress-related fatigue and burnout (no mood disorder diagnosis). The most appropriate use case. Screen for bipolar history, check the medication list for MAOI/SSRI interactions, recommend morning dosing, and book a 4-week and 12-week review. Pair with Better Access psychology where the clinical picture warrants it — the supplement is an adjunct, not a primary intervention.

Adults with mild depression. May trial rhodiola where patient preference strongly favours herbal-first, severity is genuinely mild (PHQ-9 below 10, no suicidality, functioning preserved), and bipolarity screen is negative. Document the evidence discussion, the screening, and the review schedule. Never initiate in moderate-to-severe depression (PHQ-9 ≥15), active suicidality, or postpartum depression. The RANZCP 2020 Mood CPG is the gold standard for AU treatment of mood disorders.

Athletes and shift workers. The acute attentional and reduced-perceived-exertion effects have some trial support. Confirm WADA status is not an issue, verify there is no stimulant stacking concern, and remind the patient that rhodiola is not a replacement for sleep hygiene and recovery.

Older adults. No dedicated trial data in adults over 65. The stimulating profile may be appropriate for older adults with fatigue-dominant presentations, but the CYP3A4 interaction potential warrants particular attention given polypharmacy prevalence. Hepatic function and concurrent medication review are essential before recommending.

When to escalate

Refer or escalate when:

• Mood symptoms meet criteria for major depressive disorder (PHQ-9 ≥10, two-week duration, functional impairment) — first-line psychological and pharmacological treatment per RANZCP 2020 Mood CPG; rhodiola is not appropriate as monotherapy
• Suicidal ideation at any intensity — immediate mental health assessment; any supplement conversation is premature
• Patient discloses prior manic or hypomanic episode, or significant family history of bipolar disorder — rhodiola is contraindicated; consider AMH guidance for anxiety/mood management without MAO-modulating supplements
• Burnout with organisational or occupational drivers — psychology plus occupational health; a supplement does not address the systems problem
• Suspected or established generalised anxiety disorder — cognitive behavioural therapy via Better Access plus, if pharmacotherapy indicated, eTG and AMH first-line anxiolytics; rhodiola is not guideline-aligned for diagnosed anxiety

What this article is and is not

This is general health information evaluating the available clinical trial evidence for Rhodiola rosea supplementation in the context of Australian general practice, drawing on published RCTs, systematic reviews, the TGA’s compositional guideline, the EMA HMPC herbal monograph, and the RANZCP 2020 Mood Disorder CPG. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about supplement use — particularly in the presence of mood disorders, prescription medications, or any medical condition — require individualised discussion with your own GP.

For general stress support: Healthdirect Australia; Beyond Blue 1300 22 4636; Lifeline 13 11 14 for crisis support.

---

Sources cited

1. Olsson EMG et al. — SHR-5 stress-related fatigue RCT. Planta Medica 2009
2. Edwards D et al. — WS 1375 open-label study. Phytother Res 2012
3. Hung SK et al. — Rhodiola rosea systematic review. Phytomedicine 2011
4. Mao JJ et al. — Rhodiola vs sertraline for MDD. Phytomedicine 2015
5. Darbinyan V et al. — Rhodiola rosea in mild–moderate depression. Nord J Psychiatry 2007
6. Bersani FS et al. — Mania associated with rhodiola rosea. Prim Care Companion CNS Disord 2022
7. Van Diermen D et al. — MAO inhibition by rhodiola rosea. J Ethnopharmacol 2009
8. Spanakis M et al. — Drug interactions with salidroside. Nutrients 2023
9. Lu Y et al. — Rhodiola in sports performance — systematic review. Phytother Res 2024
10. TGA — Rhodiola rosea compositional guideline
11. TGA — Listed medicines pathway
12. EMA HMPC — Rhodiola rosea herbal monograph
13. RANZCP — Clinical Practice Guidelines for Mood Disorders 2020
14. Australian Medicines Handbook
15. WADA 2026 Prohibited List
16. LiverTox — Herbal and dietary supplements chapter
17. PLoS ONE 2024 — Quality and safety of rhodiola rosea supplements
18. Healthdirect Australia — Stress management